These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
- Moderna (MRNA), 120% surge in interest
- Organigram (OGI), 106% surge in interest
- Biolinerx (BLRX), 103% surge in interest
- Iovance Biotherapeutics (IOVA), 79% surge in interest
Pipeline and key clinical candidates for these companies:
Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA, or mRNA, to "an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale," the company states. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has "allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing." Most recently, Moderna’s capabilities have come together to allow the authorized use and approval of vaccines against the COVID pandemic. The company is pursuing the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.
Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the company’s global footprint. Organigram has also developed a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, Monjour and Trailblazer.
BioLineRx is a pre-commercial-stage biopharmaceutical company focused on oncology. The company’s lead development program, motixafortide, a novel selective inhibitor of the CXCR4 chemokine receptor, may support diverse therapeutic approaches in oncology and other diseases. APHEXDA was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous transplantation for multiple myeloma patients, has reported positive results from a pre-planned pharmacoeconomic study in the U.S., and has had its NDA submission accepted by the FDA with an assigned PDUFA date of September 9, 2023. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of metastatic pancreatic cancer, or mPDAC, in combination with the PD-1 inhibitor pembrolizumab and chemotherapy and is currently being studied in combination with the PD-1 inhibitor cemiplimab and chemotherapy as a first line mPDAC therapy.
Iovance Biotherapeutics is focused on developing and delivering tumor infiltrating lymphocyte, or TIL, therapies for patients with cancer. Its lead late-stage TIL product candidate, lifileucel for metastatic melanoma, "has the potential to become the first approved one-time cell therapy for a solid tumor cancer," said the company, adding that its TIL platform has "demonstrated promising clinical data across multiple solid tumors."
Recent news on these stocks:
April 12
After Moderna hosted its annual Vaccines Day, BofA said the firm "wouldn’t be surprised if shares continue to trade under pressure" given Moderna’s seasonal flu program, mRNA-1010, received notice that the iDSMB interim review recommended continuation of efficacy follow-up. Following the delay, the firm suspects investor interest may turn to the updated mRNA-1010 flu vaccine, which is set to initiate a confirmatory phase 3 trial this month. BofA, which contends that it was "left with more questions than answers" from the event, has a Neutral rating and $200 price target on Moderna shares.
April 11
Organigram reported Q2 revenue of $39.5M vs $31.8M last year. "We are pleased with our results in a quarter with typical seasonality. Our market position remains competitive, supported by our leading brand portfolio, strong international sales and customer-focused innovation," said Beena Goldenberg, Chief Executive Officer. "Just 12 months after adding hash to our portfolio with the acquisition of our Lac Superieur facility, we gained the number one position in the hash sector and launched SHRED X Rip-Strip Hash, the first product of its kind in Canada."
Hear more from InvestingChannel by signing up for The Spill.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRNA:
